Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALC NASDAQ:MGX NASDAQ:MREO NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.86+1.2%$0.64$0.46▼$7.20$13.59M0.97792,878 shs157,976 shsMGXMetagenomi$1.33$1.38$1.24▼$3.95$50.07M0.64225,553 shs119,129 shsMREOMereo BioPharma Group$0.32-4.8%$0.30$0.20▼$3.05$50.76M0.336.82 million shs3.13 million shsXLOXilio Therapeutics$8.31+2.0%$8.30$6.47▼$12.74$54.68M-0.1241,589 shs8,269 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+6.21%+14.18%+44.44%+28.62%-47.84%MGXMetagenomi0.00%-1.48%-4.32%-17.39%-24.86%MREOMereo BioPharma Group-1.53%+1.67%+28.54%-14.53%-87.39%XLOXilio Therapeutics-0.61%-2.28%-2.04%+7.53%-13.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.86+1.2%$0.64$0.46▼$7.20$13.59M0.97792,878 shs157,976 shsMGXMetagenomi$1.33$1.38$1.24▼$3.95$50.07M0.64225,553 shs119,129 shsMREOMereo BioPharma Group$0.32-4.8%$0.30$0.20▼$3.05$50.76M0.336.82 million shs3.13 million shsXLOXilio Therapeutics$8.31+2.0%$8.30$6.47▼$12.74$54.68M-0.1241,589 shs8,269 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+6.21%+14.18%+44.44%+28.62%-47.84%MGXMetagenomi0.00%-1.48%-4.32%-17.39%-24.86%MREOMereo BioPharma Group-1.53%+1.67%+28.54%-14.53%-87.39%XLOXilio Therapeutics-0.61%-2.28%-2.04%+7.53%-13.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 2.00Hold$10.001,062.79% UpsideMGXMetagenomi 2.80Moderate Buy$9.00576.69% UpsideMREOMereo BioPharma Group 2.13Hold$3.25922.01% UpsideXLOXilio Therapeutics 2.50Moderate Buy$28.00236.94% UpsideCurrent Analyst Ratings BreakdownLatest CALC, XLO, MREO, and MGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/19/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026MGXMetagenomi Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.005/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/12/2026MREOMereo BioPharma Group BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.005/8/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/23/2026MREOMereo BioPharma Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral3/19/2026MREOMereo BioPharma Group Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/5/2026CALCCalciMedica OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $10.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/AMGXMetagenomi$25.21M1.99N/AN/A$4.22 per share0.32MREOMereo BioPharma Group$500K101.52N/AN/A$0.26 per share1.22XLOXilio Therapeutics$43.77M1.25N/AN/A$7.31 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)MGXMetagenomi-$87.87M-$2.30N/AN/AN/A-384.61%-51.23%-36.62%8/11/2026 (Estimated)MREOMereo BioPharma Group-$41.88M-$0.05N/A31.80N/AN/A-81.28%-70.45%8/11/2026 (Estimated)XLOXilio Therapeutics-$35.04M-$3.55N/A23.08N/A-58.52%-151.42%-27.61%8/13/2026 (Estimated)Latest CALC, XLO, MREO, and MGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A5/12/2026Q1 2026XLOXilio Therapeutics-$0.66-$0.58+$0.08-$0.58$8.52 million$12.65 million5/11/2026Q1 2026MGXMetagenomi-$0.60-$0.61-$0.01-$0.61$5.90 million$1.25 million3/23/2026Q4 2025XLOXilio Therapeutics-$1.68-$0.85+$0.83$0.81$10.90 million$13.69 million3/20/2026Q4 2025MREOMereo BioPharma Group-$0.01-$0.01N/A-$0.05$5.30 millionN/A3/5/2026Q4 2025MGXMetagenomi-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A1.611.61MGXMetagenomiN/A6.436.43MREOMereo BioPharma GroupN/A6.486.48XLOXilio TherapeuticsN/A3.593.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/AMGXMetagenomiN/AMREOMereo BioPharma Group62.83%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%MGXMetagenomi12.50%MREOMereo BioPharma Group6.50%XLOXilio Therapeutics7.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3015.80 million9.23 millionNo DataMGXMetagenomi23637.65 million32.94 millionN/AMREOMereo BioPharma Group40159.62 million149.24 millionOptionableXLOXilio Therapeutics706.58 million6.09 millionNot OptionableCALC, XLO, MREO, and MGX HeadlinesRecent News About These CompaniesXilio Therapeutics IncJune 2 at 7:33 AM | edition.cnn.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesMay 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?April 1, 2026 | zacks.comXilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56March 28, 2026 | msn.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comXilio Therapeutics Announces 1-for-14 Reverse Stock SplitMarch 12, 2026 | globenewswire.comXilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2, 2026 | globenewswire.comXilio Therapeutics Shareholders Approve Flexible Reverse Stock SplitFebruary 24, 2026 | tipranks.comXilio Therapeutics Announces Pricing of Underwritten OfferingFebruary 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCALC, XLO, MREO, and MGX Company DescriptionsCalciMedica NASDAQ:CALC$0.86 +0.01 (+1.15%) Closing price 03:58 PM EasternExtended Trading$0.86 +0.00 (+0.23%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Metagenomi NASDAQ:MGX$1.33 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.01 (+0.83%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Mereo BioPharma Group NASDAQ:MREO$0.32 -0.02 (-4.85%) Closing price 04:00 PM EasternExtended Trading$0.32 +0.00 (+0.94%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Xilio Therapeutics NASDAQ:XLO$8.31 +0.16 (+1.96%) Closing price 03:59 PM EasternExtended Trading$8.24 -0.07 (-0.78%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
